Episode Details
Back to EpisodesSolvonis Therapeutics: Redefining Treatment for Alcohol Use Disorder Through Capital-Efficient Innovation
Description
In this episode of WTR Small-Cap Spotlight, Anthony Tennyson, CEO and Co-Founder of Solvonis Therapeutics (LSE: SVNS | OTC: SLVNF), joins host Tim Gerdeman, Vice Chair and Co-Founder of Water Tower Research, and analyst Robert Sassoon to discuss the company’s mission to transform care for addiction and mental health disorders.
Tennyson shares Solvonis’ journey from inception to its Phase 3 lead program for alcohol use disorder (AUD), which achieved 86% patient sobriety in prior Phase 2 trials, and details how the company’s **dual R&D strategy—repurposing existing molecules and discovering new small molecules—**has allowed it to progress with exceptional capital efficiency. The discussion also covers the SVN-001 and SVN-002 programs, commercialization strategy, and Solvonis’ strong financial position and runway through 2027 as it works toward redefining treatment for one of the world’s most pervasive unmet medical needs.